LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

Table 2 LSD1 inhibitors’ effects on immune functions

SI	Name	Category	Immunologic activity	Ref
1	Phenelzine	Irreversible MAO inhibitor	• Inhibit FAD and CoREST binding to LSD1 • Increase transcription and activation of M1 macrophage signature genes • Decrease CAF-mediated resistance to chemotherapy	[56]
2	Bomedemstat	Irreversible LSD1 inhibitor	• Increase MHC-I expression • Increase CD8 T cell infiltration in tumor	[104]
3	ORY-1001	Irreversible FAD binding LSD1 inhibitor	• Combined with PD-L1 antibody therapy it increases tumor cell killing	[37]
4	SP-2577	Reversible LSD1 inhibitor	• Stimulate IFN-dependent antitumor immunity	[99]
5	GSK2879552	Irreversible LSD1 inhibitor	• Prolong responses to PD-1 blockade	[43]
6	Tranylcypromine	Irreversible LSD1 inhibitor	• Increase MHC-I stabilization • Stimulate CD8 T cell activation	[69]
7	Amsacrine derivative compound 6x	LSD1 inhibitor	• Suppress expression of PD-L1 • Promote T-cell killing response	[112]
8	Chlorpromazine derivative compound 3 s	LSD1 inhibitor	• Suppress expression of PD-L1 • Promote T-cell killing response	[113]

ISSN: 1423-0127